The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Abstract
CONTEXT: The natural history of biochemical recurrence after radical prostatectomy can be long but variable. Better risk assessment models are needed to identify men who are at high risk for prostate cancer death early and who may benefit from aggressive salvage treatment and to identify men who are at low risk for prostate cancer death and can be safely observed. OBJECTIVES: To define risk factors for prostate cancer death following radical prostatectomy and to develop tables to risk stratify for prostate cancer-specific survival. DESIGN, SETTING, AND PATIENTS: Retrospective cohort study of 379 men who had undergone radical prostatectomy at an urban tertiary care hospital between 1982 and 2000 and who had a biochemical recurrence and after biochemical failure had at least 2 prostate-specific antigen (PSA) values at least 3 months apart in order to calculate PSA doubling time (PSADT). The mean (SD) follow-up after surgery was 10.3 (4.7) years and median follow-up was 10 years (range, 1-20 years). MAIN OUTCOME MEASURE: Prostate cancer-specific mortality. RESULTS: Median survival had not been reached after 16 years of follow-up after biochemical recurrence. Prostate-specific doubling time (<3.0 vs 3.0-8.9 vs 9.0-14.9 vs > or =15.0 months), pathological Gleason score (< or =7 vs 8-10), and time from surgery to biochemical recurrence (< or =3 vs >3 years) were all significant risk factors for time to prostate-specific mortality. Using these 3 variables, tables were constructed to estimate the risk of prostate cancer-specific survival at year 15 after biochemical recurrence. CONCLUSION: Clinical parameters (PSADT, pathological Gleason score, and time from surgery to biochemical recurrence) can help risk stratify patients for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. These preliminary findings may serve as useful guides to patients and their physicians to identify patients at high risk for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy to enroll them in early aggressive treatment trials. In addition, these preliminary findings highlight that survival in low-risk patients can be quite prolonged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Han, M., Partin, A. W., Pound, C. R., Epstein, J. I., & Walsh, P. C. (2001) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70163-4 · Cited by 1,028
Self-citationCANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS
HULL, G. W., RABBANI, F., ABBAS, F., WHEELER, T. M., KATTAN, M. W., & SCARDINO, P. T. (2002) · Journal of Urology · doi:10.1016/s0022-5347(01)69079-7 · Cited by 964
ROEHL, K. A., HAN, M., RAMOS, C. G., ANTENOR, J. A. V., & CATALONA, W. J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000134888.22332.bb · Cited by 861
AMLING, C. L., BLUTE, M. L., BERGSTRALH, E. J., SEAY, T. M., SLEZAK, J., & ZINCKE, H. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67457-5 · Cited by 368
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer
Walsh, P. C. (2005) · Journal of Urology · doi:10.1016/s0022-5347(05)60500-9 · Cited by 315
Self-citation
Cited by
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., Vickers, A. J., Parwani, A. V., Reuter, V. E., Fine, S. W., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.046 · Cited by 1,374
Cancer biomarker detection: recent achievements and challenges
Wu, L., & Qu, X. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00370e · Cited by 1,214
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
Eggener, S. E., Scardino, P. T., Walsh, P. C., Han, M., Partin, A. W., Trock, B. J., Feng, Z., Wood, D. P., Eastham, J. A., Yossepowitch, O., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.057 · Cited by 640
Self-citationStephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Dotan, Z. A., Bianco, F. J., Lilja, H., & Scardino, P. T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0756 · Cited by 529
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Crook, J. M., O'Callaghan, C. J., Duncan, G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S., Chin, J., Nabid, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201546 · Cited by 499
Liu, C., Zhao, J., Tian, F., Cai, L., Zhang, W., Feng, Q., Chang, J., Wan, F., Yang, Y., Dai, B., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0343-6 · Cited by 482
Pantuck, A. J., Leppert, J. T., Zomorodian, N., Aronson, W., Hong, J., Barnard, R. J., Seeram, N., Liker, H., Wang, H., Elashoff, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2290 · Cited by 461
Cooperberg, M. R., Hilton, J. F., & Carroll, P. R. (2011) · Cancer · doi:10.1002/cncr.26169 · Cited by 457
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2501 · Cited by 419
Active surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404
American Cancer Society prostate cancer survivorship care guidelines
Skolarus, T. A., Wolf, A. M. D., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., Salner, A. L., Zelefsky, M. J., Aragon‐Ching, J. B., Slovin, S. F., et al. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21234 · Cited by 398
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D., Wong, J. Y. C., Pantel, A. R., Cho, S. Y., Gage, K. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4573 · Cited by 389
Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., Supiot, S., Bosset, M., Lagrange, J.-L., Beckendorf, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00111-x · Cited by 365
Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359
Self-citationRodriguez, C., Freedland, S. J., Deka, A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Thun, M. J., & Calle, E. E. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0754 · Cited by 354
Self-citationCooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 348
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp122 · Cited by 336
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303974 · Cited by 319
Self-citationPettersson, A., Graff, R. E., Bauer, S. R., Pitt, M. J., Lis, R. T., Stack, E. C., Martin, N. E., Kunz, L., Penney, K. L., Ligon, A. H., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0042 · Cited by 319
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
Lecouvet, F. E., El Mouedden, J., Collette, L., Coche, E., Danse, E., Jamar, F., Machiels, J.-P., Vande Berg, B., Omoumi, P., & Tombal, B. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.020 · Cited by 303
Active surveillance for early‐stage prostate cancer: Review of the current literature
Dall'Era, M. A., Cooperberg, M. R., Chan, J. M., Davies, B. J., Albertsen, P. C., Klotz, L. H., Warlick, C. A., Holmberg, L., Bailey, D. E., Wallace, M. E., et al. (2008) · Cancer · doi:10.1002/cncr.23373 · Cited by 273
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 266
Self-citationPrensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
An updated catalog of prostate cancer predictive tools
Shariat, S. F., Karakiewicz, P. I., Roehrborn, C. G., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23908 · Cited by 264
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer
Ahearn, T. U., Pettersson, A., Ebot, E. M., Gerke, T., Graff, R. E., Morais, C. L., Hicks, J. L., Wilson, K. M., Rider, J. R., Sesso, H. D., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv346 · Cited by 186
Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
Winters-Stone, K. M., Dobek, J. C., Bennett, J. A., Dieckmann, N. F., Maddalozzo, G. F., Ryan, C. W., & Beer, T. M. (2015) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2014.08.010 · Cited by 126
Ishiguro, H., Akimoto, K., Nagashima, Y., Kojima, Y., Sasaki, T., Ishiguro-Imagawa, Y., Nakaigawa, N., Ohno, S., Kubota, Y., & Uemura, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907044106 · Cited by 74
Ames, S. C., Tan, W. W., Ames, G. E., Stone, R. L., Rizzo, T. D., Crook, J. E., Williams, C. R., Werch, C. E., Clark, M. M., & Rummans, T. A. (2011) · Psycho-Oncology · doi:10.1002/pon.1769 · Cited by 21
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-27
- Volume
- 294
- Issue
- 4
- Pages
- 433
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3023689102
- Cited by
- 1,358
- References
- 21
- FWCI
- 55.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.